3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
75
Neoplasm Metastasis
12
Neoplasms
8
Ovarian Neoplasms
6
Endometrial Neoplasms
6
Pancreatic Neoplasms
5
Carcinoma, Renal Cell
5
Sarcoma
4
Neoplasms by Site
4
Lymphoma, Non-Hodgkin
4
Breast Diseases
4
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma
3
Lung Neoplasms
3
Liposarcoma
3
Kidney Neoplasms
3
Head and Neck Neoplasms
3
Glioma
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Interventions
capivasertib
2
Fulvestrant
2
ribociclib
1
palbociclib
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
palbociclib
×
1 year
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled